BioSpectrum the business of Bio & Health Sciences

IDRS Labs seeks emergency nod for plant-based drug against Long Covid

29 August 2022 | News

Completion of clinical development of Sodium Copper Chlorophyllin was done with multiple agencies

Bhabha Atomic Research Centre (BARC), Advanced Centre for Treatment, Research and Education in Cancer - Tata Memorial Centre (ACTREC-TMC) and IDRS Labs (IDRS), Bengaluru have announced the completion of Phase II clinical trial of Sodium Copper Chlorophyllin 750 mg tablets.

The phase II clinical trial was a multi-centre, randomised, open label, controlled trial of sodium-copper-chlorophyllin given along with treatment of physician’s choice versus treatment of physician’s choice in asymptomatic or mildly symptomatic patients with COVID-19.

A tripartite Memorandum of Agreement was signed among BARC, ACTREC-TMC and IDRS to develop Chlorophyllin against COVID-19 disease and other indications. The dossier is filed for 'Emergency Use Authorization (EUA)' for the treatment of SARS-CoV-2 Infection (COVID-19) by IDRS to the Drug Controller General of India (DCGI) as stated by Shivkumar Madki, Co-founder and MD, IDRS Labs.

Dr Sudeep Gupta, Director, ACTREC - Navi Mumbai, who was instrumental in designing the phase II clinical trial of Sodium Copper Chlorophyllin, observed that chlorophyllin’s ability to demonstrate anti-SARS-CoV-2 and immunomodulatory activity across model systems, combined with its excellent safety profile, makes it a possible candidate for prophylaxis against long-COVID.